U.S. Markets closed

Best NasdaqGM Growth Companies

Miguel Kauffman

Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as AcelRx Pharmaceuticals and Intersect ENT are deemed to be superior in terms of how much they’re expected to earn and return to shareholders, according to analysts. Below I’ve put together a list of great potential investments for you to consider adding to your portfolio if growth is a dimension you would like to firm up.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Established in 2005, and headed by CEO Vincent Angotti, the company employs 41 people and with the market cap of USD $127.59M, it falls under the small-cap category.

An outstanding 52.43% earnings growth is forecasted for ACRX, driven by strong underlying sales growth over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. ACRX’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Thinking of investing in ACRX? Other fundamental factors you should also consider can be found here.

NasdaqGM:ACRX Future Profit May 6th 18

Intersect ENT, Inc. (NASDAQ:XENT)

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. Founded in 2003, and headed by CEO Lisa Earnhardt, the company provides employment to 327 people and with the company’s market capitalisation at USD $1.26B, we can put it in the small-cap category.

An outstanding 72.28% earnings growth is forecasted for XENT, driven by the underlying 57.48% sales growth over the next few years. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. We see this bottom-line expansion directly benefiting shareholders, with expected positive return on equity of 8.26%. XENT’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Thinking of investing in XENT? Check out its fundamental factors here.

NasdaqGM:XENT Future Profit May 6th 18

Gulfmark Offshore, Inc. (AMEX:GLF)

GulfMark Offshore, Inc. provides offshore marine support and transportation services primarily to the companies involved in the offshore exploration and production of oil and natural gas. Established in 1996, and headed by CEO Quintin Kneen, the company currently employs 530 people and with the market cap of USD $250.95M, it falls under the small-cap category.

An outstanding 99.49% earnings growth is forecasted for GLF, driven by an underlying sales growth of 34.23% over the next few years. Although reduction in cost is not the most sustainable operational activity, the expanding top-line growth, on the other hand, is encouraging. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 1.07%. GLF’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Could this stock be your next pick? Have a browse through its key fundamentals here.

AMEX:GLF Future Profit May 6th 18

For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.